Myra Vision
- Industry
- Medical Devices & Equipment
- Founded Year
- 2016
- Headquarters
- 1717 Dell Ave, Campbell, California, 95008, United States
- Employee Count
- 6
Key People
- Robert Chang - President & CEO
- Signe Erickson, Ph.D. - Chief Operating Officer
- Amr Salahieh - Co-Founder & Chairman
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The leadership team comprises experienced professionals with over a decade in the medical device industry.
Robert Chang, President & CEO, and Signe Erickson, COO, bring significant industry experience, positioning Myra Vision favorably in the market.
- Clinical Need
-
Aspect: Very Strong
Summary: Myra Vision addresses a critical need for effective treatments for moderate to severe glaucoma.
With over 66 million people affected by glaucoma worldwide, and a substantial portion requiring significant IOP reduction, Myra Vision's Calibreye System offers a promising solution.
- Competition
-
Aspect: Somewhat crowded
Summary: The glaucoma treatment market has several players, but Myra Vision's approach offers differentiation.
Companies like Glaukos and Nova Eye Medical operate in the same space, but Myra Vision's Calibreye System's personalized approach could set it apart.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing adjustable outflow control systems presents moderate technical challenges.
The development of the Calibreye System involves integrating nanotechnology for precise IOP control, which, while complex, is achievable given the team's expertise.
- Patent
-
Aspect: Strong
Summary: Myra Vision has secured strong patent protection for its technology.
The company's innovative approach to glaucoma treatment is safeguarded by strong patents, providing a barrier to entry for competitors.
- Financing
-
Aspect: Well-funded
Summary: Myra Vision has successfully raised significant funding to support its development.
With a $25 million Series B financing in June 2023, led by reputable investors, Myra Vision is well-positioned financially to advance its initiatives.
- Regulatory
-
Aspect: Running FIH
Summary: The company is conducting first-in-human trials for its Calibreye System.
Initiating first-in-human trials indicates progress, but further stages are required to achieve full regulatory approval and market entry.
Opportunity Rollup
- Odds of Success
- 3.85
- Peak Market Share
- 5.6
- Segment CAGR
- 3.2%
- Market Segment
- Ophthalmic Devices
- Market Sub Segment
- Glaucoma Treatment Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.28 |
| 2 | 0.84 |
| 3 | 1.96 |
| 4 | 3.92 |
| 5 | 5.60 |
Key Takeaway
Myra Vision's innovative approach to glaucoma treatment, supported by a strong team and substantial funding, positions it well in a competitive market, though challenges remain in regulatory approval and market adoption.